Topic
Psychotropic drug
About: Psychotropic drug is a research topic. Over the lifetime, 2309 publications have been published within this topic receiving 54070 citations.
Papers published on a yearly basis
Papers
More filters
TL;DR: The effects of various phenothiazine derivatives and several other psychiatric drugs on six different commercial immunologic pregnancy tests found one of the commercial techniques consistently gave false positive reactions, which were not dose related or attributable to any particular psychotropic drug.
11 citations
TL;DR: The association of family health and family structure factors with psychotropic drug consumption, alcohol abuse, and minor psychiatric morbidity was investigated in a representative community sample of 151 respondents by means of a logistic multiple regression analysis.
11 citations
TL;DR: Beside some methodological restrictions like inconsistent information of weight changes and the small sample of available long term studies, this review specifies the incidence of weight change for commonly used psychotropic drugs and might be helpful to look for alternatives.
Abstract: OBJECTIVE
The purpose of this study is to give a systematic review of change of weight associated with commonly used psychotropic drugs.
METHODS
Mainly based on a MEDLINE-supported review until April 2005, data from clinical studies with antidepressants, anticonvulsants, mood stabilizers and neuroleptics were scanned for change of weight during treatment.
RESULTS
Among antidepressants amitryptiline and nortriptyline have the highest incidence of weight gain followed by imipramine. Maprotiline and mirtazapine have an intermediate weight increasing potential. SSRI (except paroxetine) and MAOI had no or only slight weight inducing effects. In contrary, bupropion was associated with weight reduction. Regarding mood stabilizers and anticonvulsants, a marked gain in weight with lithium and sodium valproate was reported frequently. With gabapentin and vigabatrin a slight to moderate gain in weight was found. Minor changes of weight were found with carbamazepine and lamotrigine. Treatment with topiramate and felbamate reportedly lead to weight loss. The atypical neuroleptics clozapine and olanzapine were frequently related to a strong gain in weight followed by risperidone. Quetiapine has intermediate effects. Stable weight was found with aripiprazole and ziprasidone. A gain in weight is less frequent with older/typical neuroleptics.
CONCLUSION
Beside some methodological restrictions like inconsistent information of weight changes (e. g. percent vs. mass) and the small sample of available long term studies, this review specifies the incidence of weight changes for commonly used psychotropic drugs and might be helpful to look for alternatives.
11 citations
TL;DR: Over one-third of the neurologist's most commonly administered medications were those also employed by the psychiatrist, but not necessarily for the same reason, e.g., carbamazepine, for seizure control (neurologist) or mood stabilization (psychiatrist).
11 citations
TL;DR: In this paper, the authors focused on HIV-infected individuals with no history of injecting drug use (IDU) or hepatitis C virus (HCV) infection, and found that HIV infection was associated with a higher utilization of psychotropic drugs than the background population, which was not confined to individuals with a history of IDU or HCV infection.
Abstract: Objectives
The objective was to estimate the utilization of psychotropic drugs in HIV-infected individuals compared with that in the background population.
Methods
Using data obtained from the Danish HIV Cohort Study and the Danish National Prescription Registry, we analysed aggregated data on redeemed prescription of psychotropic drugs during 1995–2009. We primarily focused our analyses on HIV-infected individuals with no history of injecting drug use (IDU) or hepatitis C virus (HCV) infection. Drug utilization was expressed as defined daily doses per 1000 person-days (DDD/1000PD). The utilization rate ratio (URR) was calculated as utilization in the HIV-infected cohort compared with that in the comparison cohort. We estimated longitudinal trends in utilization and potential associations with HIV and exposure to highly active antiretroviral therapy (HAART), especially efavirenz.
Results
During 1995–2009, 54.5% of the HIV-infected cohort (3615 non-IDU/non-HCV-infected HIV-infected individuals) and 29.2% of the comparison cohort (32 535 individuals) had at least one prescription of a psychotropic drug. HIV infection was associated with a URR of 1.13 for antipsychotics, 1.76 for anxiolytics, 4.42 for hypnotics and sedatives, and 2.28 for antidepressants. Antidepressants were confined primarily to men who have sex with men (MSM). Older age, more recent calendar time, and increased time after HIV diagnosis were associated with increased drug utilization. However, no association with exposure to HAART or efavirenz was found.
Conclusions
HIV-infected individuals had a higher utilization of psychotropic drugs than the background population, which was not confined to individuals with a history of IDU or HCV infection. This emphasizes the need to focus on diagnosis of, and appropriate psychopharmacological interventions for, mental disorders in this population.
11 citations